Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹3,108 Cr
Revenue (TTM)
₹674 Cr
Net Profit (TTM)
₹203 Cr
ROE
40.5 %
ROCE
51.8 %
P/E Ratio
15.3
P/B Ratio
5.4
Industry P/E
32.2
EV/EBITDA
18.8
Div. Yield
1.3 %
Debt to Equity
0
Book Value
₹348.3
EPS
₹63.5
Face value
8
Shares outstanding
16,539,015
CFO
₹536.83 Cr
EBITDA
₹731.89 Cr
Net Profit
₹507.00 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
RPG Life Sciences
| -19.1 | -2.4 | -19.8 | -17.4 | 38.1 | 37.1 | 23.2 |
|
BSE Healthcare
| -2.6 | -1.7 | -3.7 | 3.2 | 25.2 | 15.5 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
RPG Life Sciences
| 5.7 | 63.9 | 57.7 | 37.0 | 64.6 | 15.8 | 30.6 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
RPG Life Sciences
|
1,879.7 | 3,107.9 | 673.7 | 202.6 | 17.6 | 19.4 | 15.3 | 5.4 |
| 343.2 | 3,134.2 | 2,521.8 | 202.5 | 9.6 | 14.3 | 15.5 | 2.1 | |
| 949.8 | 11,646.5 | 2,512.3 | 543.7 | 28.3 | 19.3 | 21.4 | 3.7 | |
| 358.0 | 6,205.7 | 1,053.1 | 293.6 | 32.3 | 24.6 | 21.1 | 4.8 | |
| 1,092.3 | 11,428.8 | 1,158.7 | 309.6 | 31.9 | 17.3 | 36.6 | 6.0 | |
| 1,478.2 | 28,010.9 | 8,850.1 | 894.8 | 15.2 | 19.8 | 32.2 | 5.6 | |
| 273.5 | 2,997.6 | 159.3 | 47.8 | 39.0 | 18.6 | 62.7 | 10.8 | |
| 11,995.0 | 15,402.0 | 1,575.1 | 179.1 | 14.9 | 11.4 | 86 | 9.3 | |
| 751.6 | 3,460.7 | 588.5 | 102.9 | 22.1 | 12.7 | 34.1 | 4.1 | |
| 134.0 | 3,532.5 | 7.1 | -274.7 | -4,008.3 | -140.4 | -- | 5.3 |
No Review & Analysis are available.
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs... in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmentics, anti-convulsant, and anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and finished dosage formulations for various therapies, which include nephrology, rheumatology, oncology, gastroenterology, cardiology, orthopedics, nutritional, diabetology, respiratory, neuropsychiatry, urology, vitamins and minerals, gastrointestinal, pain management, anti-diabetic, gynecology, cardiovascular, pediatrics, neurology, anti-dengue, and dermatology, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust. Read more
Incorporated
2007
Chairman
Harsh Goenka
Managing Director
Ashok Nair
Group
RPG Enterprises
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of RPG Life Sciences Ltd is ₹1,879.70 (NSE) and ₹1,879.10 (BSE) as of 20-Mar-2026 IST. RPG Life Sciences Ltd has given a return of 38.1% in the last 3 years.
The P/E ratio of RPG Life Sciences Ltd is 15.34 times as on 20-Mar-2026, a 52 discount to its peers’ median range of 32.20 times.
The P/B ratio of RPG Life Sciences Ltd is 5.39 times as on 20-Mar-2026, a 150 premium to its peers’ median range of 2.16 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
20.56
|
7.10
|
|
2024
|
28.87
|
6.75
|
|
2023
|
17.01
|
3.74
|
|
2022
|
17.98
|
3.62
|
|
2021
|
16.00
|
2.96
|
The 52-week high and low of RPG Life Sciences Ltd are Rs 2,725.00 and Rs 1,764.20 as of 21-Mar-2026.
RPG Life Sciences Ltd has a market capitalisation of ₹ 3,108 Cr as on 20-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in RPG Life Sciences Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹56.80
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.